Sort
16,300 grants matching “fatty liver disease”
Project 3: CYP2E1 Regulation of Ethanol-Induced miRNAs in Intestinal Epithelial Cells
$224,250Je-Hyun Yoon · Medical University Of South Carolina · P20 · FY2020 · GM
Project 4: Impact of the Gut Microbiome on Liver Innate Immunity and Skeletal Function
$224,250Chad Michael Novince · Medical University Of South Carolina · P20 · FY2020 · GM
Screening for LXR agonists-inhibitors of brain amyloidosis and inflammation
$224,241Iliya Lefterov · University Of Pittsburgh At Pittsburgh · R21 · FY2008 · AG
Mechanisms in Metabolic Control in C. elegans.
$224,197Amy Karol Walker · Massachusetts General Hospital · R01 · FY2011 · DK
Identification and characterization of early encystation genes in the human parasite Entamoeba histolytica
$224,191Cheryl Jean Ingram-Smith · Clemson University · R21 · FY2023 · AI
Role of Clock-Modulating Small Molecules Against Aging
$224,070Zheng Chen · University Of Texas Hlth Sci Ctr Houston · R01 · FY2015 · AG
Molecular Determinants of Tumor Progression in A Steatolic Liver Microenvironment
$224,069David L Gorden · Vanderbilt University · U01 · FY2012 · CA
Community Engagement Core
$223,929Dwayne Edward Porter · University Of South Carolina At Columbia · P01 · FY2019 · ES
Role of brown and beige fat in alcoholic liver disease
$223,891Liangyou Rui · University Of Michigan At Ann Arbor · R21 · FY2018 · AA
Novel insulin-sensitizing NASH/diabetes drugs.
$223,817Timothy R Peterson · Bioio, Llc · R42 · FY2019 · DK
METABOLIC CORE
$223,797Jacob E Friedman · University Of Colorado Denver · P30 · FY2010 · DK
Inhibition of Liver Fibrosis by Oxysterol Drug Candidates in a Mouse Model of NASH
$223,696Farhad Parhami · Max Biopharma, Inc. · R43 · FY2020 · DK
Hepatitis B Clinical Research Network
$223,662Richard K. Sterling · Virginia Commonwealth University · U01 · FY2011 · DK
Postnatal Complications and Interventions against Halogenated Organics during Pregnancy
$223,500Kevin Joseph Pearson · University Of Kentucky · P42 · FY2020 · ES
Fatty Acid Synthase Inhibitors As Broad Spectrum Anti-Flaviviral Therapeutics
$223,414Glenn C Randall · University Of Chicago · R21 · FY2012 · AI
Evaluation of individual FMT as a potential therapeutic to reduce ethanol drinking in mice
$223,172Jasmohan S Bajaj · Virginia Commonwealth University · R21 · FY2025 · AA
Identification of biomarkers for biochemical, pathophysiological and neurological effects of high ammonia concentration on the central nervous system in a preclinical model of neonatal hyperammonemia
$223,125Ljubica Morizono Caldovic · Children'S Research Institute · R21 · FY2022 · HD
Sphingosine-1 phosphate signaling in alcoholic liver disease
$223,112Huiping Rose Zhou · Virginia Commonwealth University · R21 · FY2019 · AA
Development of the GlycoFibrotyper for detection of liver fibrosis
$223,055Danielle Scott · Glycopath, Inc · R41 · FY2019 · DK
Therapeutic Restoration of Metabolic Homeostasis During Active TB
$223,050Randall J Basaraba · Colorado State University · R21 · FY2014 · AI
MITOCHONDRIAL SHORT CHAIN 3-OH-ACYL-COA DEHYDROGENASES
$222,931Vanderbilt University · R01 · FY2000 · DK
Risk of xenobiotic-drug interactions in chronic disease
$222,910John Daniel Clarke · Washington State University · R56 · FY2020 · AT
Adipocytes and Botanicals/Jacequeline M. Stephens
$222,813William T. Cefalu · Lsu Pennington Biomedical Research Ctr · P50 · FY2014 · AT
Encapsulated RNAs in extracellular vesicles contribute ALD progression
$222,813Akiko Eguchi · University Of California, San Diego · R21 · FY2015 · AA
AMPK Signaling and Chronic Alcoholic Pancreatitis
$222,813Bhupendra S Kaphalia · University Of Texas Med Br Galveston · R21 · FY2016 · AA